Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives

Phytotherapy Research

Volumn 25, Issue 11, 2011, Pages 1671-1677

  Zhao, Ting ^a   He, Yu Qi ^a   Wang, Jun ^a   Ding, Ke Min ^a   Wang, Chang Hong ^a,b,c   Wang, Zheng Tao ^a,b,c  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b MOE Key Laboratory for Standardization of Chinese Medicines   (China)

^c Shanghai R and D Center for Standardization of Chinese Medicines   (China)

Author keywords

carboline alkaloids; CYP2D6; CYP3A4; Harmine derivatives; Inhibition; Peganum harmala

Indexed keywords

BETA CARBOLINE DERIVATIVE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HARMALINE; HARMALOL; HARMAN; HARMINE; HARMOL;

ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LIVER MICROSOME; PEGANUM HARMALA; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; HARMINE; HUMANS; MICROSOMES, LIVER; PEGANUM; PLANTS, MEDICINAL;

NICOTIANA TABACUM; PEGANUM HARMALA;

EID: 80054956542     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3458     Document Type: Article

References (32)

1. Agúndez JA, Jiménez-Jiménez FJ, Luengo A et al. 1995. Association between the oxidative polymorphism and the early onset of Parkinson's disease. Clin Pharmacol Ther 57: 291-298.
2. Arshad N, Neubauer C, Hasnain S, Hess M. 2008. Peganumharmala can minimize Escherichia coli infection in poultry, but long-term feeding may induce side effects. Poult Sci 87: 240-249. (Pubitemid 351198488)
3. Astulla A, Zaima K, Matsuno Y et al. 2008. Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities. Nat Med 62: 470-472.
4. Bouchardy C, Benhamou S, Dayer P. 1996. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56: 251-253. (Pubitemid 26026349)
5. Coleman MD. 2005. Human Drug Metabolism: An Introduction. Wiley-Blackwell:Chichester,30.
6. Copeland RA. 2000. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, 2nd edn. Wiley-VCH: New York, 350-366.
7. Fan ZR, Yao XS. 1992. Chemical and pharmacology studies on the plants of Peganum. J Shenyang Pharm Univ 9: 144-151.
8. Farouk L, Laroubi A, Aboufatima R, Benharref A, Chait A. 2008. Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L possible mechanisms involved. J Ethnopharmacol 115: 449-454. (Pubitemid 350299085)
9. Foti RS, Pearson JT, Rock DA, Wahlstrom JL, Wienkers LC. 2009. In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. Drug Metab Dispos 37:1848-1855.
10. Guan Y, Louis ED, Zheng W. 2001. Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats. J Toxicol Environ Health A 64:645-660. (Pubitemid 33132019)
11. Guengerich FP. 1999. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39: 1-17. (Pubitemid 29222549)
12. Herraiz T, Guillén H, Arán VJ. 2008. Oxidative metabolism of the bioactive and naturally occurring β-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes. Chem Res Toxicol 21: 2172-2180.
13. Jahaniani F, Ebrahimi SA, Rahbar-Roshandel N, Mahmoudian M. 2005. Xanthomicrol is the main cytotoxic component of Dracocephalum kotschyii and a potential anti-cancer agent. Phytochemistry 66: 1581-1592. (Pubitemid 40950551)
14. Jones DR, Gorski JC, Hamman MA, Hall SD. 1996. Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B Biomed Appl 678: 105-111. (Pubitemid 26114746)
15. Kim H, Sablin SO, Ramsay RR. 1997. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 337: 137-142. (Pubitemid 27198065)
16. Lewis DF, Ioannides C, Parke DV, Schulte-Hermann R. 2000. Quantitative structure-activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis. J Steroid Biochem Mol Biol 74: 179-185. (Pubitemid 32121653)
17. Liu Y, Ma H, Zhang JW, Deng MC, Yang L. 2006. Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes. Planta Med 72: 126-131. (Pubitemid 43293866)
18. Moura DJ, Rorig C, Vieira DL et al. 2006. Effects of β-carboline alkaloids on the object recognition task in mice. Life Sci 79: 2099-2104. (Pubitemid 44573274)
19. Prashanth D, John S. 1999. Antibacterial activity of Peganum harmala. Fitoterapia 70: 438-439. (Pubitemid 29422648)
20. Qiu F, Zhang R, Sun J et al. 2008. Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 36: 1308-1314. (Pubitemid 351929315)
21. Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. 2003. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306: 73-83. (Pubitemid 36734359)
22. Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD. 2003. Activities of extract and constituents of Banisteriopsis caapi relevant to Parkinsonism. Pharmacol Biochem Behav 75: 627-633. (Pubitemid 36936896)
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423. (Pubitemid 24229655)
24. Smith DA, Jones BC. 1992. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44: 2089-2098.
25. Tahraoui A, El-Hilaly J, Israili ZH, Lyoussi B. 2007. Ethnopharmacological survey of plants used in the traditional treatment of hypertension and diabetes in south-eastern Morocco (Errachidia province). J Ethnopharmacol 110: 105-117. (Pubitemid 46217839)
26. Tang JC, Yang H, Song XY et al. 2009. Inhibition of cytochrome P450 enzymes by rhein in rat liver microsomes. Phytother Res 23: 159-164.
27. Walsky RL, Obach RS. 2004. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32: 647-660. (Pubitemid 38668158)
28. Wang CH, Liu J, Zheng LM. 2002. Analysis of harmine and harmaline of Peganum harmala in different parts of different localities. Chin Pharm J 37: 212-215.
29. Wu C, Jiang XL, Shen HW, Yu AM. 2009. Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol 78: 617-624.
30. Yu AM, Idle JR, Krausz KW, Küpfer A, Gonzalez FJ. 2003. Contribution of individual cytochrome P450 isozymes to the o-demethylation of the psychotropic α-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305: 315-322. (Pubitemid 36373866)
31. Zheng XY, Zhang ZJ, Chou GX et al. 2009. Acetylcholinesterase inhibitive activity-guided isolation of two new alkaloids from seeds of Peganum nigelastrum Bunge by an in vitro TLC bioautographic assay. Arch Pharm Res 32: 1245-1251.
32. Zhou S, Huang M, Xu A, Yang H, Duan W, Paxton JW. 2005. Prediction of herb-drug metabolic interactions: a simulation study. Phytother Res 19: 464-471. (Pubitemid 41345519)